Liquidia Corp

Liquidia Corp (LQDA) Annual Report: A 2025 Snapshot

This report offers a concise overview of Liquidia Corp's performance for the fiscal year ended December 31, 2025. Liquidia (LQDA) is a biopharmaceutical company focused on developing innovative treatments. The company operates as a "Smaller Reporting Company" and "Non-accelerated Filer" with the SEC. This classification, based on its public market value and revenue, means Liquidia provides slightly less detailed financial disclosures and benefits from extended filing deadlines compared to larger entities.

Business Overview

Liquidia Corp is a biopharmaceutical company that develops and commercializes innovative products for patients with life-limiting diseases. The company uses its proprietary PRINT® technology to create precisely engineered particles, enhancing drug delivery. Liquidia's main focus is YUTREPIA (treprostinil) inhalation powder, an investigational drug for Pulmonary Arterial Hypertension (PAH), a serious and progressive lung disease. Liquidia's strategy centers on securing regulatory approval for YUTREPIA, preparing for its commercial launch, and exploring further applications for its technology.

Financial Performance

For the full year 2025, Liquidia's financial highlights include:

• Total Revenues: Approximately $0.5 million, primarily from collaborations.
• Net Loss: About $85 million. This significant loss reflects substantial investments in research and development and pre-launch activities, typical for a biopharmaceutical company in its development phase.
• Cash Position: As of December 31, 2025, Liquidia held approximately $140 million in cash and cash equivalents.
• Market Capitalization: With roughly 88.1 million shares outstanding as of February 2026 and a stock price around $12.46 (as of mid-2025), the company's approximate market capitalization is $1.1 billion.

Risk Factors

Investing in Liquidia involves specific risks:

• Regulatory Hurdles: FDA approval for YUTREPIA is not guaranteed. Delays or requests for additional data could impact the company's ability to generate revenue.
• Legal Battles: The ongoing patent dispute with United Therapeutics presents a significant risk. It could affect YUTREPIA's launch timeline, market access, or future revenues, potentially leading to substantial legal costs or adverse judgments.
• Financial Sustainability: Liquidia operates with a significant cash burn rate due to its substantial net loss. While the company holds cash, it may need to raise additional capital in the future. This could dilute existing shareholders or be unavailable on favorable terms.
• Market Adoption: Even if approved, YUTREPIA faces competition. Gaining widespread acceptance among physicians and patients, and securing adequate insurance reimbursement, poses a challenge that could limit its commercial success.
• Product Concentration: Liquidia's success heavily relies on YUTREPIA. Any clinical, regulatory, legal, or commercial setbacks with this single product could significantly impact the company's financial health and stock performance.
• Intellectual Property Protection: Protecting its intellectual property, including patents and trade secrets, is crucial for Liquidia's success. Challenges to its IP could undermine its competitive position.

Management Discussion and Analysis (MD&A) Highlights

Management emphasizes the company's strategic focus on advancing YUTREPIA towards commercialization. The substantial net loss in 2025 reflects significant investments in:

• Research and development activities, including clinical trials.
• Manufacturing scale-up.
• Pre-commercialization efforts for YUTREPIA.

Key operational highlights include:

• Navigating the FDA's review process for YUTREPIA's New Drug Application (NDA).
• Actively engaging in ongoing patent litigation with United Therapeutics, a critical factor for YUTREPIA's potential market entry.

Management is also preparing for successful commercialization by:

• Developing market access strategies.
• Building a commercial infrastructure.
• Engaging with key opinion leaders and patient advocacy groups to support YUTREPIA's potential market adoption.

While the company's cash position currently funds operations for a certain period, management continuously evaluates capital needs given the high burn rate typical of a development-stage biopharmaceutical company.

Financial Health

As of December 31, 2025, Liquidia held approximately $140 million in cash and cash equivalents. These funds are crucial for its ongoing operations, research and development, and pre-commercialization activities. The company, typical of a development-stage entity, operates with a significant cash burn rate. While current cash reserves provide liquidity, Liquidia recognizes it may need to raise additional capital in the future through equity or debt financings to achieve its long-term strategic objectives. Such financings could dilute existing shareholders.

Future Outlook

Liquidia's strategy for the coming year focuses on the successful launch and commercialization of YUTREPIA, contingent on clearing regulatory and legal hurdles. The company aims to position YUTREPIA as a leading PAH treatment by highlighting its clinical benefits and ease of use, and by securing broad market access and favorable insurance coverage. Beyond YUTREPIA, Liquidia plans to continue exploring its pipeline for future product development using its PRINT® technology and remains committed to protecting its intellectual property. Achieving these strategic objectives heavily depends on favorable outcomes from the FDA review process and the ongoing patent litigation.

Competitive Position

The market for Pulmonary Arterial Hypertension (PAH) treatments is highly competitive, featuring established pharmaceutical companies with approved therapies. Key competitors offer prostacyclin analogs (like United Therapeutics' Tyvaso and Remodulin), endothelin receptor antagonists, and phosphodiesterase-5 inhibitors.

Liquidia aims to differentiate YUTREPIA with its unique inhalation powder formulation. This formulation could offer advantages in:

• Patient convenience
• Adherence
• Potentially an improved efficacy or safety profile compared to existing nebulized or infused treatments.

Liquidia's competitive strategy focuses on:

• Demonstrating YUTREPIA's clinical benefits.
• Securing regulatory approval.
• Effectively managing intellectual property.
• Building a robust commercial infrastructure to gain market share against entrenched competitors.

Ultimately, investing in Liquidia right now means betting on YUTREPIA's success through regulatory approval, legal battles, and market adoption, balanced against the company's current cash position and high burn rate.